Repositioning Candidate Details
| Candidate ID: | R0901 |
| Source ID: | DB05939 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | MK-0354 |
| Synonyms: | -- |
| Molecular Formula: | C7H8N6 |
| SMILES: | C1CC2=C(C1)C(=NN2)C1=NNN=N1 |
| Structure: |
|
| DrugBank Description: | MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin. |
| CAS Number: | 851776-28-8 |
| Molecular Weight: | 176.183 |
| DrugBank Indication: | Investigated for use/treatment in atherosclerosis. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | -- |
| Targets: | G-protein coupled estrogen receptor 1 |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I07 | 1936 | Arteriosclerosis | Build-up of fatty material and calcium deposition in the arterial wall resulting in partial or complete occlusion of the arterial lumen.https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C35768 | disease of anatomical entity/cardiovascular system disease/ vascular disease/ artery disease | Details |